Becton Dickinson — Feb 9, 2026 release

Page 8 BECTON DICKINSON AND COMPANY SUPPLEMENTAL INFORMATION FY 2026 OUTLOOK RECONCILIATION New BD (Post-Disposition of Biosciences and Diagnostic Solutions business) Full Year FY2025 Full Year FY2026 Outlook ($ in millions) % Change BDX Reported Revenues $ 21,840  Less: Life Sciences Segment Revenues 3,296  New BD Revenues $ 18,544  FY2026 Reported Revenue Growth Low single-digit plus Illustrative Foreign Currency (FX) Impact ~+120 basis points FY2026 Revenue Growth (FXN) Low single-digit Page 9 BECTON DICKINSON AND COMPANY SUPPLEMENTAL INFORMATION FY 2026 OUTLOOK RECONCILIATION CONTINUED New BD (Post-Disposition of Biosciences and Diagnostic Solutions business) Full Year FY2025 Total Company (Pre-Disposition of Biosciences and Diagnostics Solutions business) Full Year FY2025 Estimated impact from disposition of Biosciences and Diagnostics Solutions business (1) Full Year FY2025 excluding Biosciences and Diagnostics Solutions business Full Year FY2026 New BD (Post-Disposition of Biosciences and Diagnostic Solutions business) Reported Diluted Earnings per Share $ 5.82  Purchase accounting adjustments ($1.898 billion pre-tax) (2) 6.58 Integration costs ($127 million pre-tax) (3) 0.44 Restructuring costs ($275 million pre-tax) (3) 0.95 Transaction costs ($6 million pre-tax) (4) 0.02 Separation-related items ($97 million pre-tax) (5) 0.34 Product, litigation, and other items ($548 million pre-tax) (6) 1.90 Tax impact of specified items and other tax related (($473) million) (1.64) Adjusted Diluted Earnings per Share $ 14.40  ~($2.60) ~$11.80 $12.35 to $12.65 Reported % Change +4.7% to +7.2% (1) Amount reflects the estimated impact to adjusted diluted earnings per share for fiscal year 2025 from the proposed disposition of the Bioscience and Diagnostics Solutions business that will be separated and combined with Waters Corporation. Actual impact to adjusted diluted earnings per share may differ from the estimate as certain amounts are finalized. (2) Includes amortization and other adjustments related to the purchase accounting for acquisitions. (3) Represents costs associated with integration and restructuring activities. (4) Represents transaction costs incurred in connection with the Advanced Patient Monitoring acquisition. (5) Represents costs recorded to Other operating expense, net, incurred in connection with the proposed combination of our Biosciences and Diagnostic Solutions business with Waters Corporation. (6) Includes certain (income) expense items which are not part of ordinary operations and affect the comparability of the periods presented. Such items may include certain product remediation costs, certain legal matters, certain investment gains and losses, certain asset impairment charges, and certain pension settlement costs. The amount in 2025 reflects